Floatz logo

Carboplatin

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue

National Cancer Institute (NCI)Small moleculePhase 2Dormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
81/ 100

Competitive context

36 Active assets in the Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
SWOG Cancer Research Network
Phase 2BBB
DEXAMETHASONE
Izidore Lossos, MD
Phase 2BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
City of Hope Medical Center
Phase 3BBB
Fludarabine
UNC Lineberger Comprehensive Cancer Center
Phase 2BB
VINCRISTINE SULFATE
SWOG Cancer Research Network
Phase 2BB

View all 50 →

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →